Published in J Immunol Res on July 31, 2016
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods (2004) 3.53
The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut (2010) 2.61
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol (2007) 2.35
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol (2011) 1.33
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol (2013) 1.32
The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res (2013) 1.24
Differential effect of drug interference in immunogenicity assays. J Immunol Methods (2011) 1.17
Identification and inhibition of drug target interference in immunogenicity assays. J Immunol Methods (2010) 1.04
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis (2013) 0.99
Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods (2012) 0.97
IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol (2012) 0.96
Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods (2011) 0.94
General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem (2012) 0.93
Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure. AAPS J (2012) 0.90
An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods (2007) 0.90
Rapid affinity measurement of protein-protein interactions in a microfluidic platform. Anal Biochem (2012) 0.89
Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul Toxicol Pharmacol (2007) 0.88
Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J Immunol Methods (2008) 0.87
A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies. Nephrol Dial Transplant (2012) 0.85
A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies. Biomed Chromatogr (2012) 0.85
Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J Immunol Methods (2010) 0.85
Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. Anal Chem (2008) 0.84
Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J Pharm Biomed Anal (2010) 0.84
Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity. MAbs (2015) 0.84
Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1a. Bioanalysis (2015) 0.83
Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients. Bioanalysis (2015) 0.82
Evaluation of acoustic membrane microparticle (AMMP) technology for a sensitive ligand binding assay to support pharmacokinetic determinations of a biotherapeutic. AAPS J (2014) 0.82
Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development. Anal Chem (2014) 0.81
Measuring biotherapeutics with endogenous counterparts and pre-existing antibodies: an interferon case study. Bioanalysis (2014) 0.81
Protein-based matrix interferences in ligand-binding assays. Bioanalysis (2014) 0.81
Validation of a microfluidic platform to measure total therapeutic antibodies and incurred sample reanalysis performance. Bioanalysis (2014) 0.80
Validation of a Gyrolab™ assay for quantification of rituximab in human serum. J Pharmacol Toxicol Methods (2012) 0.80
Immuno-PCR assays for immunogenicity testing. Biochem Biophys Res Commun (2009) 0.80
Universal immunogenicity validation and assessment during early biotherapeutic development to support a green laboratory. Bioanalysis (2013) 0.80
Feasibility of immuno-PCR technology platforms as an ultrasensitive tool for the detection of anti-drug antibodies. Bioanalysis (2015) 0.79
Generic anti-drug antibody assay with drug tolerance in serum samples from mice exposed to human antibodies. Anal Biochem (2012) 0.78
Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing. AAPS J (2014) 0.78
Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic. Bioanalysis (2012) 0.78
Microfluidic analysis of antibody specificity in a compact disk format. J Proteome Res (2006) 0.77
Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development. J Immunol Res (2016) 0.76
Development of a Generic Anti-PEG Antibody Assay Using BioScale's Acoustic Membrane MicroParticle Technology. AAPS J (2015) 0.76
Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and Semiquantitation. J Immunol Res (2016) 0.76
Development and validation of an alpha fetoprotein immunoassay using Gyros technology. J Pharm Biomed Anal (2012) 0.76
Matrix interference from Fc-Fc interactions in immunoassays for detecting human IgG4 therapeutics. Bioanalysis (2015) 0.75
Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development. J Immunol Res (2016) 0.75
Bridging immunogenicity assays for IgG4 therapeutics: mitigating interference from Fc-Fc interactions. Bioanalysis (2017) 0.75